Most of the antiseizure medications(ASMs)are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury.Hence,treatment of new onset se...Most of the antiseizure medications(ASMs)are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury.Hence,treatment of new onset seizures or epilepsy by ASMs during the course of coronavirus disease 2019(COVID-19),which could potentially be complicated by hepatic dysfunction,is a challenging clinical issue.Intravenous form of levetiracetam which has no significant hepatic metabolism or drug-drug interaction is often a favorable option to control seizures in acute phase of COVID-19.Administration of enzyme inducer ASMs and valproate with the well-known hepatotoxicity and common drug interactions is not generally recommended.In patients with epilepsy who are under control with potentially hepatotoxic ASMs,close observation and cautious dose reduction or drug switch should be considered if any evidence of hepatic impairment exists.However,risks of possible breakthrough seizures should be weighed against benefits of lowering the hazard of liver injury.In patients with epilepsy who receive polytherapy with ASMs,transient dose modification with the tendency to increase the dose of ASMs with more favorable safety profile and less drug interaction and decrease the dose of drugs with main hepatic metabolism,high protein binding,potential to cause liver injury and known drug-drug reaction should be considered.Finally,decision making should be individualized based on patients’conditions and course of illness.展开更多
文摘Most of the antiseizure medications(ASMs)are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury.Hence,treatment of new onset seizures or epilepsy by ASMs during the course of coronavirus disease 2019(COVID-19),which could potentially be complicated by hepatic dysfunction,is a challenging clinical issue.Intravenous form of levetiracetam which has no significant hepatic metabolism or drug-drug interaction is often a favorable option to control seizures in acute phase of COVID-19.Administration of enzyme inducer ASMs and valproate with the well-known hepatotoxicity and common drug interactions is not generally recommended.In patients with epilepsy who are under control with potentially hepatotoxic ASMs,close observation and cautious dose reduction or drug switch should be considered if any evidence of hepatic impairment exists.However,risks of possible breakthrough seizures should be weighed against benefits of lowering the hazard of liver injury.In patients with epilepsy who receive polytherapy with ASMs,transient dose modification with the tendency to increase the dose of ASMs with more favorable safety profile and less drug interaction and decrease the dose of drugs with main hepatic metabolism,high protein binding,potential to cause liver injury and known drug-drug reaction should be considered.Finally,decision making should be individualized based on patients’conditions and course of illness.
